miRecule Names J&J Pharma Vet Fu-An Kang to Lead Growing Research Team

Published on :

miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule after serving for 6 years as the Senior Director of Chemistry at Abzena, a leading chemistry, biologics and antibody-drug conjugate (ADC) research organization.

miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy

Published on :

miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.

NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.

Published on :

Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.

Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy

Published on :

miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.

End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region

Published on :

This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.

BioHealth Capital Region Startups Raised More Than $739M in 2019

Published on :

BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]

The 2nd Annual Tech Showcase Reflects New Culture at NCI & FNLCR

Published on :

The 2nd Annual Tech Showcase Reflects New Culture at NCI & FNLCR When you hear the term “government research” do the words “entrepreneur”, “start-up”, “commercially relevant” or “industry partner” come to [….]